Pharmacogenetics has been promoted as potentially providing benefits to patients, managed care organizations and pharmaceutical companies. This has not translated into products that benefit healthcare developers, providers or consumers. The reasons for this are many, but this will change as the fina
β¦ LIBER β¦
Pharmacogenetics of the neurodevelopmental impact of anticancer chemotherapy
β Scribed by Philippe Robaey; Maja Krajinovic; Sophie Marcoux; Albert Moghrabi
- Publisher
- Wiley (John Wiley & Sons)
- Year
- 2008
- Tongue
- English
- Weight
- 170 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1940-5510
- DOI
- 10.1002/ddrr.29
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The impact of pharmacogenetics on the fu
β
Jay B Lichter; Janice H Kurth
π
Article
π
1997
π
Elsevier Science
π
English
β 353 KB
Chemotherapy of neuroblastoma in mice wi
β
George C. Y. Chiou; Marilyn K. Martin
π
Article
π
1980
π
John Wiley and Sons
π
English
β 345 KB
Metallothionein and anticancer agents: t
β
FranΓ§ois Doz; Norbert Roosen; Mark L. Rosenblum
π
Article
π
1993
π
Springer US
π
English
β 587 KB
Pharmacogenetics and population pharmaco
β
Julie Bertrand; Emmanuelle Comets; CΓ©line M. Laffont; Marylore Chenel; France Me
π
Article
π
2009
π
Springer
π
English
β 750 KB
Prognostic impact of anticancer immune r
β
Franck PagΓ©s; Guido Kroemer
π
Article
π
2011
π
Springer-Verlag
π
English
β 68 KB
Databases in the area of pharmacogenetic
β
Sarah C. Sim; Russ B. Altman; Magnus Ingelman-Sundberg
π
Article
π
2011
π
John Wiley and Sons
π
English
β 139 KB
π 1 views
In the area of pharmacogenetics and personalized health care it is obvious that databases, providing important information of the occurrence and consequences of variant genes encoding drug metabolizing enzymes, drug transporters, drug targets, and other proteins of importance for drug response or to